Centessa Pharmaceuticals PLC - CNTA EV/EBITDA Multiple

Corporate emblem and logo of Centessa Pharmaceuticals PLC (CNTA)

Centessa Pharmaceuticals (CNTA) scalability is based on the simultaneous development of several scientific projects to capture the global market. The company's EV/EBITDA chart clearly demonstrates this trend, where the 0.00 metric determines the parameter status. Patents that reduce costs create the foundation for stability, while the flawless operation of certified laboratories guarantees the uninterrupted conduct of clinical trials for new molecules.

CNTA (Centessa Pharmaceuticals PLC) EV/EBITDA Multiple history from 11/23/2025 to 07/04/2026

CNTA (Centessa Pharmaceuticals plc): analytical breakdowns and indicator data

- market price and analyst price targets:
Summary company analytics:CNTA (Centessa Pharmaceuticals plc)
Original product of Centessa

To identify fundamental stability drivers, an investor analyzes the ratio of enterprise value (including net debt) to earnings before interest, taxes, depreciation, and amortization, which reveals the asset's real value independent of tax influence. The current EV/EBITDA multiple reflects the efficiency of the Centessa Pharmaceuticals (CNTA) decentralized model, weighing the holding company's capital expenditures on the development of rare genetic drugs against its ability to generate cash flow.

Competitor analysis

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Jazz Pharmaceuticals plc JAZZ|CYTK: Enterprise Value to Operating Income Before Depreciation|PTC Bio - EV/EBITDA Multiple|Company Value to EBITDA Scholar Rock Corp|Dyne Pharma (DYN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Edgewise Corp (EWTX) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Rapport Therapeutics, Inc.|ALMS: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Zevra Corp (ZVRA)|CTNM - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Larimar Pharma LRMR|Capricor Therapeutics - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|TRDA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Channel Therapeutics|MNOV: EV/EBITDA Multiple|Company Value to EBITDA Serina Therapeutics Inc (SER)|Enterprise Value to EBITDA Ratio BTAI|promisneurosciences.com - Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple APUS|EV/EBITDA Multiple AEON Biopharma, Inc. (AEON)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NLS Pharma NLSP|Total Company Value to Operating Income Before Depreciation Ratio Bionomics Limited (BNOX)|FSD Pharma Inc. - EV/EBITDA Multiple|RETA - EV/EBITDA Multiple